Sigit Adi Prasetyo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sigit Adi Prasetyo has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Muflihatul Muniroh
Department of Physiology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
3 shared publications Agung Aji Prasetyo
Pediatric Surgery Division, Surgery Department, Faculty of Medicine Diponegoro University / Kariadi Central Hospital, Semarang, Indonesia
2 shared publications- Endang Sri Lestari
Department of Clinical Microbiology, Faculty of Medicine, Universitas Diponegoro, Indonesia
2 shared publications - Ignatius Riwanto
Division of Digestive Surgery, Department of Surgery, Kariadi Hospital, Semarang, Indonesia
2 shared publications - Selamat Budijitno
Department of Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
2 shared publications - Agung Aji Prasetyo
Gastroentero-Hepatology Division, Department of Internal Medicine, Dr Kariadi Hospital, Indonesia
1 shared publication
Latest Publications
- 9 June 2026
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 23 (3) , em741
Comparison of pathogen patterns in benign and malignant obstruction in cholangitis patients: A systematic review
Background: Cholangitis is a serious bile duct infection caused by obstruction that permits bacterial growth and may progress to sepsis. Management includes antibiotics and biliary drainage, but selection is challenged by antibiotic resistance and differing pathogen patterns between benign and malignant obstruction. This systematic review aimed to compare the prevalence and distribution of pathogens identified in bile, blood, and biliary stent cultures between benign and malignant biliary obstruction in patients with cholangitis. Methods: A systematic search of PubMed, Scopus, and ScienceDirect (January 1, 2014-October 17, 2024) identified cohort, case-control, and cross-sectional studies comparing microbial profiles in benign versus malignant cholangitis. Non-English articles, case reports, randomized trials, and reviews were excluded. Results: Eight studies involving 3,575 patients were included. Culture positivity was generally higher in benign obstruction (bile 55.7% vs. 44.3%; blood 19.6% vs. 14.2%). Escherichia coli was most frequently isolated, followed by Enterococcus spp., Klebsiella pneumoniae, and Pseudomonas aeruginosa. Malignant cases more often yielded Candida spp. and viridans-group streptococci from stents. Conclusion: Distinct pathogen patterns may inform empirical therapy, though further research is needed.
- 9 June 2026
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 23 (3) , em741
Comparison of pathogen patterns in benign and malignant obstruction in cholangitis patients: A systematic review
Background: Cholangitis is a serious bile duct infection caused by obstruction that permits bacterial growth and may progress to sepsis. Management includes antibiotics and biliary drainage, but selection is challenged by antibiotic resistance and differing pathogen patterns between benign and malignant obstruction. This systematic review aimed to compare the prevalence and distribution of pathogens identified in bile, blood, and biliary stent cultures between benign and malignant biliary obstruction in patients with cholangitis. Methods: A systematic search of PubMed, Scopus, and ScienceDirect (January 1, 2014-October 17, 2024) identified cohort, case-control, and cross-sectional studies comparing microbial profiles in benign versus malignant cholangitis. Non-English articles, case reports, randomized trials, and reviews were excluded. Results: Eight studies involving 3,575 patients were included. Culture positivity was generally higher in benign obstruction (bile 55.7% vs. 44.3%; blood 19.6% vs. 14.2%). Escherichia coli was most frequently isolated, followed by Enterococcus spp., Klebsiella pneumoniae, and Pseudomonas aeruginosa. Malignant cases more often yielded Candida spp. and viridans-group streptococci from stents. Conclusion: Distinct pathogen patterns may inform empirical therapy, though further research is needed.
- Open Access
- 1 April 2026
- Published by Al-Rafidain University College in Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
- Vol. 10 (2) , 61-63
Giant Serous Cystadenoma of The Pancreatic Tail: Diagnostic Significance of CT Scanning in a Rare Case
Giant serous cystadenoma (SCA) of the pancreas is a rare benign tumor that typically remains asymptomatic and undetected until it reaches a considerable size, highlighting the diagnostic challenge in differentiating it from other pancreatic cystic lesions. This study seeks to present an uncommon instance of giant pancreatic SCA and underscore the diagnostic and therapeutic methodology. A case report design was used involving a 35-year-old female patient presenting with a painless epigastric mass without associated gastrointestinal or systemic symptoms. Physical examination revealed a firm, non-tender mass in the left upper abdomen. Diagnostic imaging using contrast-enhanced computed tomography (CT) identified a 15 cm multiloculated cystic lesion with thin septations and central calcifications in the body and tail of the pancreas. Surgical intervention consisted of distal pancreatectomy and splenectomy. Histopathological examination confirmed a diagnosis of serous cystadenoma confined to the pancreatic tail, characterized by multiple cystic spaces lined with cuboidal epithelium and clear cytoplasm. The patient experienced an uneventful recovery and was discharged on the fifth postoperative day. This case underscores the critical role of radiologic evaluation in differentiating SCAs from other cystic lesions such as pseudocysts and mucinous cystadenomas to support accurate preoperative planning. The findings suggest that, despite their benign nature, early recognition and surgical management of large SCAs are essential to preventing complications, and improved awareness is needed to enhance diagnostic accuracy and avoid overtreatment or delayed intervention.
- 1 April 2026
- Published by Al-Rafidain University College in Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
- Vol. 10 (2) , 61-63
Open AccessGiant Serous Cystadenoma of The Pancreatic Tail: Diagnostic Significance of CT Scanning in a Rare Case
Giant serous cystadenoma (SCA) of the pancreas is a rare benign tumor that typically remains asymptomatic and undetected until it reaches a considerable size, highlighting the diagnostic challenge in differentiating it from other pancreatic cystic lesions. This study seeks to present an uncommon instance of giant pancreatic SCA and underscore the diagnostic and therapeutic methodology. A case report design was used involving a 35-year-old female patient presenting with a painless epigastric mass without associated gastrointestinal or systemic symptoms. Physical examination revealed a firm, non-tender mass in the left upper abdomen. Diagnostic imaging using contrast-enhanced computed tomography (CT) identified a 15 cm multiloculated cystic lesion with thin septations and central calcifications in the body and tail of the pancreas. Surgical intervention consisted of distal pancreatectomy and splenectomy. Histopathological examination confirmed a diagnosis of serous cystadenoma confined to the pancreatic tail, characterized by multiple cystic spaces lined with cuboidal epithelium and clear cytoplasm. The patient experienced an uneventful recovery and was discharged on the fifth postoperative day. This case underscores the critical role of radiologic evaluation in differentiating SCAs from other cystic lesions such as pseudocysts and mucinous cystadenomas to support accurate preoperative planning. The findings suggest that, despite their benign nature, early recognition and surgical management of large SCAs are essential to preventing complications, and improved awareness is needed to enhance diagnostic accuracy and avoid overtreatment or delayed intervention.
- Open Access
- 1 July 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (4) , 1160-1167
Probiotic and ursodeoxycholic acid combination improves microbial gut dysbiosis and bilirubin levels in cholestatic rats
Context: Cholestasis is marked by a disturbance in bile flow from the liver and potentially progresses to cirrhosis. Hepatic transplantation is the mainstay of therapy in hepatic cirrhosis, which is a high-cost, time-consuming, and complex procedure. Increasing evidence regarding the major role of gut microbiota in bile acid metabolism has prompted the effort to study probiotics as a potential alternative therapeutic strategy in chronic liver disease. Aims: To explore the effect of probiotic administration on Bifidobacterium, as part of the gut microbiota, and bilirubin levels in mice with cholestasis after biliary duct ligation who received standard ursodeoxycholic acid (UDCA) therapy. Methods: Thirty-five male Sprague Dawley rats were randomly assigned into seven groups: Sham-operated rats as healthy controls, cholestatic rats as negative control, UDCA only, probiotics only, and three groups received UDCA-probiotics on a stratified dose for 21 days. The bile duct ligation (BDL) procedure was used to induce cholestasis. Biochemical analyses were conducted for direct and total bilirubin levels, while Bifidobacterium DNA quantification was assessed with PCR. Results: BDL induces cholestasis, marked by a significant increase in direct and total bilirubin levels. The combination of UDCA-probiotics increased the amount of Bifidobacterium, with the highest dose of probiotics showing the highest amount, and the results were comparable among the other groups. The lowest direct and total bilirubin levels were found in the groups with the highest probiotics dose and UDCA combination. Conclusions: UDCA and probiotic combination significantly improved the amount of Bifidobacterium and bilirubin levels in cholestatic rats.
- 1 July 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (4) , 1160-1167
Open AccessProbiotic and ursodeoxycholic acid combination improves microbial gut dysbiosis and bilirubin levels in cholestatic rats
Context: Cholestasis is marked by a disturbance in bile flow from the liver and potentially progresses to cirrhosis. Hepatic transplantation is the mainstay of therapy in hepatic cirrhosis, which is a high-cost, time-consuming, and complex procedure. Increasing evidence regarding the major role of gut microbiota in bile acid metabolism has prompted the effort to study probiotics as a potential alternative therapeutic strategy in chronic liver disease. Aims: To explore the effect of probiotic administration on Bifidobacterium, as part of the gut microbiota, and bilirubin levels in mice with cholestasis after biliary duct ligation who received standard ursodeoxycholic acid (UDCA) therapy. Methods: Thirty-five male Sprague Dawley rats were randomly assigned into seven groups: Sham-operated rats as healthy controls, cholestatic rats as negative control, UDCA only, probiotics only, and three groups received UDCA-probiotics on a stratified dose for 21 days. The bile duct ligation (BDL) procedure was used to induce cholestasis. Biochemical analyses were conducted for direct and total bilirubin levels, while Bifidobacterium DNA quantification was assessed with PCR. Results: BDL induces cholestasis, marked by a significant increase in direct and total bilirubin levels. The combination of UDCA-probiotics increased the amount of Bifidobacterium, with the highest dose of probiotics showing the highest amount, and the results were comparable among the other groups. The lowest direct and total bilirubin levels were found in the groups with the highest probiotics dose and UDCA combination. Conclusions: UDCA and probiotic combination significantly improved the amount of Bifidobacterium and bilirubin levels in cholestatic rats.
- Open Access
- 27 December 2024
- Published by Universitas Islam Indonesia (Islamic University of Indonesia) in Jurnal Kedokteran dan Kesehatan Indonesia
- p. 310-318
Exploring the remarkable effect of ursodeoxycholic acid and Allium sativum combination on MMP-9 and TIMP-1 levels in cholestatic rat’s model
Background: Cholestasis is a disturbance in the production or flow of bile that causes excessive accumulation of bile fluid and damage in the liver. Chronic liver damage will lead to liver fibrosis. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitors of metalloprotease-1 (TIMP-1) play a critical role in liver fibrosis formation. Although ursodeoxycholic acid (UDCA) and Allium sativum extracts have long been renowned for improving liver function, their combination in alleviating liver fibrosis through the MMP-9 and TIMP-1 inhibitory pathways has yet to be studied.Objective: This study was conducted to assess the efficacy of UDCA and Allium sativum extract combination in altering MMP-9 and TIMP-1 levels, which are the main factors in the progression of liver fibrosis.Methods: We performed an experimental study with a post-test-only control group on 36 Sprague-Dawley rats, which were randomly grouped into healthy, negative, positive, and three treatment groups with UDCA (13.5 mg) and graded doses of Allium sativum extract (3.6 mg; 7.2 mg; and 14.4 mg). Cholestasis induction was done by a choledochal duct ligation, and treatment was given for 14 days. Levels of MMP-9 and TIMP-1 were analyzed after treatment.Results: Combining UDCA and Allium sativum improved the MMP-9 levels significantly in cholestatic rats, compared to administrating UDCA only (p <0.05). Combining UDCA and Allium sativum increased the TIMP-1 level (p < 0.05). Although the MMP-9 level results were under our existing hypothesis, TIMP-1 results showed surprising results. Matrix metalloproteinase-9 levels were strongly negatively correlated with TIMP-1 levels, with a r-value= 0.981.Conclusion: Combining Allium sativum and UDCA alleviates liver fibrosis progression through lowering levels of MMP-9 and increasing levels of TIMP-1.
- 27 December 2024
- Published by Universitas Islam Indonesia (Islamic University of Indonesia) in Jurnal Kedokteran dan Kesehatan Indonesia
- p. 310-318
Open AccessExploring the remarkable effect of ursodeoxycholic acid and Allium sativum combination on MMP-9 and TIMP-1 levels in cholestatic rat’s model
Background: Cholestasis is a disturbance in the production or flow of bile that causes excessive accumulation of bile fluid and damage in the liver. Chronic liver damage will lead to liver fibrosis. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitors of metalloprotease-1 (TIMP-1) play a critical role in liver fibrosis formation. Although ursodeoxycholic acid (UDCA) and Allium sativum extracts have long been renowned for improving liver function, their combination in alleviating liver fibrosis through the MMP-9 and TIMP-1 inhibitory pathways has yet to be studied.Objective: This study was conducted to assess the efficacy of UDCA and Allium sativum extract combination in altering MMP-9 and TIMP-1 levels, which are the main factors in the progression of liver fibrosis.Methods: We performed an experimental study with a post-test-only control group on 36 Sprague-Dawley rats, which were randomly grouped into healthy, negative, positive, and three treatment groups with UDCA (13.5 mg) and graded doses of Allium sativum extract (3.6 mg; 7.2 mg; and 14.4 mg). Cholestasis induction was done by a choledochal duct ligation, and treatment was given for 14 days. Levels of MMP-9 and TIMP-1 were analyzed after treatment.Results: Combining UDCA and Allium sativum improved the MMP-9 levels significantly in cholestatic rats, compared to administrating UDCA only (p <0.05). Combining UDCA and Allium sativum increased the TIMP-1 level (p < 0.05). Although the MMP-9 level results were under our existing hypothesis, TIMP-1 results showed surprising results. Matrix metalloproteinase-9 levels were strongly negatively correlated with TIMP-1 levels, with a r-value= 0.981.Conclusion: Combining Allium sativum and UDCA alleviates liver fibrosis progression through lowering levels of MMP-9 and increasing levels of TIMP-1.
- Open Access
- 31 August 2023
- Published by Universitas Islam Indonesia (Islamic University of Indonesia) in Jurnal Kedokteran dan Kesehatan Indonesia
- p. 153-162
Effects of ursodeoxycholic acid and glutathione combination in spleen TNF-α and apoptotic index in rats with cholestasis
Background: Cholestasis is a disorder of the formation or flow of bile. Among its contributors, tumour necrosis factor (TNF)-α stands out as the most influential inducer of apoptosis. Meanwhile, ursodeoxycholic acid (UDCA) is a valuable agent with choleretic properties, protecting the hepatobiliary system. Glutathione (GSH) enhances endothelial response and prevents liver fibrosisObjectives: This study evaluates the effect of a combination of GSH-UDCA on splenic TNF-α expression and apoptosis index in Sprague Dawley (SD) rats with cholestasisMethods: This experiment with a post-tests-only control group design involving 28 male SD rats. They were randomly into four groups: group (K) with 20 mg UDCA, group 1 (P1) with 10 mg UDCA + 10 mg GSH, group 2 (P2) was given UDCA 20 mg + GSH 15 mg, and group 3 (P3) was given UDCA 30 mg + GSH 20 mg. Cholestasis was obtained by ligation of the common bile duct through a laparotomy. During three weeks of trial, rats were administered daily with UDCA orally and GSH intramuscularly. On day 22, rats were sacrificed and spleen samples were taken for anatomical pathology examination. Results: There were significant differences in TNF-α expression between groups K vs P3; P1 vs P3, and P2 vs P3 (p=0.002). There was a significant difference in the apoptotic index between groups K vs P1 (p<0.001); K vs P2 (p=0.004), and K vs P3 (p=0.005).Conclusions: The UDCA-GSH combination demonstrated a prophylactic effect in SD rats with cholestasis and might be an effective supplemental therapy with UDCA for cholestatic diseases. The difference in TNF-α expression and apoptotic index was lower in SD rats UDCA-glutathione combination group than single dose UDCA. Between TNF-α and the apoptotic index, there is a moderate positive relation.
- 31 August 2023
- Published by Universitas Islam Indonesia (Islamic University of Indonesia) in Jurnal Kedokteran dan Kesehatan Indonesia
- p. 153-162
Open AccessEffects of ursodeoxycholic acid and glutathione combination in spleen TNF-α and apoptotic index in rats with cholestasis
Background: Cholestasis is a disorder of the formation or flow of bile. Among its contributors, tumour necrosis factor (TNF)-α stands out as the most influential inducer of apoptosis. Meanwhile, ursodeoxycholic acid (UDCA) is a valuable agent with choleretic properties, protecting the hepatobiliary system. Glutathione (GSH) enhances endothelial response and prevents liver fibrosisObjectives: This study evaluates the effect of a combination of GSH-UDCA on splenic TNF-α expression and apoptosis index in Sprague Dawley (SD) rats with cholestasisMethods: This experiment with a post-tests-only control group design involving 28 male SD rats. They were randomly into four groups: group (K) with 20 mg UDCA, group 1 (P1) with 10 mg UDCA + 10 mg GSH, group 2 (P2) was given UDCA 20 mg + GSH 15 mg, and group 3 (P3) was given UDCA 30 mg + GSH 20 mg. Cholestasis was obtained by ligation of the common bile duct through a laparotomy. During three weeks of trial, rats were administered daily with UDCA orally and GSH intramuscularly. On day 22, rats were sacrificed and spleen samples were taken for anatomical pathology examination. Results: There were significant differences in TNF-α expression between groups K vs P3; P1 vs P3, and P2 vs P3 (p=0.002). There was a significant difference in the apoptotic index between groups K vs P1 (p<0.001); K vs P2 (p=0.004), and K vs P3 (p=0.005).Conclusions: The UDCA-GSH combination demonstrated a prophylactic effect in SD rats with cholestasis and might be an effective supplemental therapy with UDCA for cholestatic diseases. The difference in TNF-α expression and apoptotic index was lower in SD rats UDCA-glutathione combination group than single dose UDCA. Between TNF-α and the apoptotic index, there is a moderate positive relation.
- Open Access
- 1 December 2022
- Published by Secretariat of The Indonesian Biomedical Journal in The Indonesian Biomedical Journal
- Vol. 14 (4) , 429-35
Combination of Ursodeoxycholic Acid and Glutathione Improves Intestinal Morphology in Cholestasis by Downregulating TNF-α Expression
BACKGROUND: Cholestasis caused by obstruction of the common bile duct and may developed gut-derived sepsis due to reactive oxygen species (ROS) accumulation. Ursodeoxycholic acid (UDCA) and glutathione are widely known for their antioxidant properties, that might be beneficial against ROS. However, the effects of UDCA-glutathione combination against ROS have not been well elucidated in previous studies. Thus, this study was conducted to evaluate tumor necrosis factor (TNF)-α level and height of terminal ileal mucosal villus after UDCA-glutathione administration in cholestasis rat model. METHODS: Twenty-eight male Sprague Dawley rats were randomly grouped into four treatment groups, each group consisted of seven rats that had previously undergone bile duct ligation. Three groups received treatment of UDCA-glutathione combination on stratified dose, while the other one only received UDCA. Each treatment was given for 21 days. Ileal samples were collected from the rats and stained with mouse anti TNF-a antibody and hematoxylin-eosin (HE). Immunohistochemistry and histopathological examination were done using microscope and then calculated with ImageJ. RESULTS: The combination of UDCA and glutathione treatment decreased the TNF-α expression (ppppCONCLUSION: UDCA-glutathione combination downregulates TNF-α expression and improves ileum mucosal villus height in cholestasis. KEYWORDS: cholestasis, glutathione, intestinal villus height, TNF-α, UDCA
- 1 December 2022
- Published by Secretariat of The Indonesian Biomedical Journal in The Indonesian Biomedical Journal
- Vol. 14 (4) , 429-35
Open AccessCombination of Ursodeoxycholic Acid and Glutathione Improves Intestinal Morphology in Cholestasis by Downregulating TNF-α Expression
BACKGROUND: Cholestasis caused by obstruction of the common bile duct and may developed gut-derived sepsis due to reactive oxygen species (ROS) accumulation. Ursodeoxycholic acid (UDCA) and glutathione are widely known for their antioxidant properties, that might be beneficial against ROS. However, the effects of UDCA-glutathione combination against ROS have not been well elucidated in previous studies. Thus, this study was conducted to evaluate tumor necrosis factor (TNF)-α level and height of terminal ileal mucosal villus after UDCA-glutathione administration in cholestasis rat model. METHODS: Twenty-eight male Sprague Dawley rats were randomly grouped into four treatment groups, each group consisted of seven rats that had previously undergone bile duct ligation. Three groups received treatment of UDCA-glutathione combination on stratified dose, while the other one only received UDCA. Each treatment was given for 21 days. Ileal samples were collected from the rats and stained with mouse anti TNF-a antibody and hematoxylin-eosin (HE). Immunohistochemistry and histopathological examination were done using microscope and then calculated with ImageJ. RESULTS: The combination of UDCA and glutathione treatment decreased the TNF-α expression (ppppCONCLUSION: UDCA-glutathione combination downregulates TNF-α expression and improves ileum mucosal villus height in cholestasis. KEYWORDS: cholestasis, glutathione, intestinal villus height, TNF-α, UDCA
- Open Access
- 31 March 2021
- Published by Institute of Research and Community Services Diponegoro University (LPPM UNDIP) in Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)
- Vol. 10 (2) , 112-117
The Difference of Length of Stay, Surgical Site Infection, Post Surgical Pain, and Bile Leak in Laparoscopic Cholecystectomy and Open Cholecystectomy
Background: The incidence of cholesistolithiasis is increased due to the changes of diet to the western diet. The cholecystectomy is one of the treatments for cholecystolithiasis. It can be divided into laparoscopic cholecystectomy and laparotomy cholecystectomi. The previous study demonstrated that the laparoscopic cholecystectomy was better than laparotomy cholecystectomy for postoperative length of stay, surgical site infection, postoperative pain, and bile leak in cholecystolithiasis, but there is no official data and research yet in Indonesia Objective: To determine the difference of postoperative length of stay, surgical site infection, postoperative pain, and bile leak in laparoscopic cholecystectomy and laparotomy cholecystectomy.Methods: An analytic observational study with cross sectional design. Subject was patient who had undergone laparoscopic or laparotomy cholecystectomy from Dr Kariadi Hospital, Semarang and RSND Semarang during period of 2013 to 2019. The Mann Whitney-U test was used to determine the difference of length of stay as well the Chi Square test for determining the difference of surgical site infection, postoperative pain, and bile leak among both groups.Results: 34 (41.5%) men and 48 (58.5%) women with an age avarage of 49.84 ± 13.54 years were included. There were a significant difference between laparoscopic and laparotomy cholecystectomy in cholecystectolithiasis cases on postoperative hospital stay (p = 0.000), postoperative pain (p = 0.000), surgical site nfection (p = 0.000), and bile leak ( p = 0.013).Conclusion: Laparoscopic cholecystectomy was better than open cholecystectomy in postoperative hospital stay, surgical site infection, postoperative pain, and bile leak for cholecystolithiasis cases. Keywords: bile leak , cholecystetomy, cholecystolithiasis, laparoscopy, laparotomy
- 31 March 2021
- Published by Institute of Research and Community Services Diponegoro University (LPPM UNDIP) in Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)
- Vol. 10 (2) , 112-117
Open AccessThe Difference of Length of Stay, Surgical Site Infection, Post Surgical Pain, and Bile Leak in Laparoscopic Cholecystectomy and Open Cholecystectomy
Background: The incidence of cholesistolithiasis is increased due to the changes of diet to the western diet. The cholecystectomy is one of the treatments for cholecystolithiasis. It can be divided into laparoscopic cholecystectomy and laparotomy cholecystectomi. The previous study demonstrated that the laparoscopic cholecystectomy was better than laparotomy cholecystectomy for postoperative length of stay, surgical site infection, postoperative pain, and bile leak in cholecystolithiasis, but there is no official data and research yet in Indonesia Objective: To determine the difference of postoperative length of stay, surgical site infection, postoperative pain, and bile leak in laparoscopic cholecystectomy and laparotomy cholecystectomy.Methods: An analytic observational study with cross sectional design. Subject was patient who had undergone laparoscopic or laparotomy cholecystectomy from Dr Kariadi Hospital, Semarang and RSND Semarang during period of 2013 to 2019. The Mann Whitney-U test was used to determine the difference of length of stay as well the Chi Square test for determining the difference of surgical site infection, postoperative pain, and bile leak among both groups.Results: 34 (41.5%) men and 48 (58.5%) women with an age avarage of 49.84 ± 13.54 years were included. There were a significant difference between laparoscopic and laparotomy cholecystectomy in cholecystectolithiasis cases on postoperative hospital stay (p = 0.000), postoperative pain (p = 0.000), surgical site nfection (p = 0.000), and bile leak ( p = 0.013).Conclusion: Laparoscopic cholecystectomy was better than open cholecystectomy in postoperative hospital stay, surgical site infection, postoperative pain, and bile leak for cholecystolithiasis cases. Keywords: bile leak , cholecystetomy, cholecystolithiasis, laparoscopy, laparotomy
- Open Access
- 1 April 2011
- Published by International College of Surgeons in International Surgery
- Vol. 96 (2) , 164-170
Effect of Phaleria Macrocarpa Supplementation on Apoptosis and Tumor Growth of C3H Mice With Breast Cancer Under Treatment With Adriamycin–Cyclophosphamide
The objective of this study was to know the response of supplementation of Phaleria macrocarpa (PM) to adriamycin-cyclophosphamide (AC) in the treatment of C3H mice with breast cancer. Twenty-four C3H mice, who were successfully inoculated with breast cancer cells, were randomly allocated into 4 groups: without treatment, treated with AC, treated with AC + PM 0.07 mg/d, and treated with AC + PM 0.14 mg/d. The tumor size was measured using millimeter calipers before and 12 weeks after treatment. The tumor, liver, and kidneys were removed and prepared for pathologic examination using imunohistochemistry staining, and the apoptotic index was counted using the terminal deoxynucleotidyl transferase dUTP nick end labeling method. AC reduce the tumor growth significantly (P < 0.001), whereas supplementation of PM, which significantly reduced the tumor growth compared with AC only, was at the 0.14 mg/d dose (P = 0.007). AC increase the apoptotic index significantly (P < 0.001), and supplementation with PM showed that the higher dose increased the apoptotic index. The correlation between the apoptotic index and the diameter of tumor was significantly negative (r = −0.884; P = 0.020). The apoptotic index of the liver and kidney increased significantly in the AC group (P < 0.001 and P = 0.002, respectively); supplementation with PM decreased significantly the high apoptotic index caused by AC. We conclude that PM supplementation has a synergic effect to AC treatment in reducing the tumor growth, by increasing apoptosis, and protects the liver and kidney from damage caused by AC.
- 1 April 2011
- Published by International College of Surgeons in International Surgery
- Vol. 96 (2) , 164-170
Open AccessEffect of Phaleria Macrocarpa Supplementation on Apoptosis and Tumor Growth of C3H Mice With Breast Cancer Under Treatment With Adriamycin–Cyclophosphamide
The objective of this study was to know the response of supplementation of Phaleria macrocarpa (PM) to adriamycin-cyclophosphamide (AC) in the treatment of C3H mice with breast cancer. Twenty-four C3H mice, who were successfully inoculated with breast cancer cells, were randomly allocated into 4 groups: without treatment, treated with AC, treated with AC + PM 0.07 mg/d, and treated with AC + PM 0.14 mg/d. The tumor size was measured using millimeter calipers before and 12 weeks after treatment. The tumor, liver, and kidneys were removed and prepared for pathologic examination using imunohistochemistry staining, and the apoptotic index was counted using the terminal deoxynucleotidyl transferase dUTP nick end labeling method. AC reduce the tumor growth significantly (P < 0.001), whereas supplementation of PM, which significantly reduced the tumor growth compared with AC only, was at the 0.14 mg/d dose (P = 0.007). AC increase the apoptotic index significantly (P < 0.001), and supplementation with PM showed that the higher dose increased the apoptotic index. The correlation between the apoptotic index and the diameter of tumor was significantly negative (r = −0.884; P = 0.020). The apoptotic index of the liver and kidney increased significantly in the AC group (P < 0.001 and P = 0.002, respectively); supplementation with PM decreased significantly the high apoptotic index caused by AC. We conclude that PM supplementation has a synergic effect to AC treatment in reducing the tumor growth, by increasing apoptosis, and protects the liver and kidney from damage caused by AC.